ClinicalTrials.gg
Not yet recruitingNCT07752069Updated Aug 7, 2026

Phase I Clinical Study Evaluating the Relative Bioavailability of Different Formulations of HRS-5346 in Healthy Participants

A Phase 1 interventional study of HRS-5346 and HRS-5346 in Lipoprotein Disorder, sponsored by Shandong Suncadia Medicine Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a single center, randomized, open label crossover trial planned to include 50 healthy participants to evaluate the relative bioavailability of HRS-5346 new and old formulations in healthy participants. The experimental process includes three stages: screening period, baseline period, and administration observation period.

02

Conditions studied

  • Lipoprotein Disorder
03

In context

Lead sponsor

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary signing of ICF prior to trial initiation; full understanding of trial content, procedures, and potential AEs; willingness to strictly adhere to the protocol and complete the trial.
  2. Age 18-45 years (inclusive) on ICF signing date; male or female.
  3. Body weight ≥ 50 kg (male) or ≥ 45 kg (female); between 19 and 28 kg/m² (inclusive).
  4. No abnormalities in vital signs, physical examination, laboratory tests, 12-lead , abdominal ultrasound, or chest X-ray (or CT), per investigator assessment; ≤ 450 ms (male) or ≤ 470 ms (female) on 12-lead ECG.
  5. Willingness to use effective (participants and partners) from ICF signing to 2 weeks post-last dose; negative serum pregnancy test and non-lactating status for female participants.

Exclusion criteria

Exclusion Criteria:

  1. Those with any clinically serious diseases judged by the investigator involving the circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry, and metabolic abnormalities, or other diseases or medical histories that may interfere with the trial results;
  2. Those with malignant tumors, or a history of malignant tumors within 5 years before screening (except for non-melanoma skin cancer that has been treated with no signs of recurrence, and resected cervical intraepithelial neoplasia);
  3. Those who have taken any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before screening, or who are still within 5 half-lives of the above drugs at the time of screening (whichever is longer);
  4. Those who plan to take medications other than the trial drug during the trial period;
  5. Those who have participated in any clinical trial of drugs or medical devices within 3 months before screening (participation in a clinical trial is defined as: having given for a clinical trial and having used the trial drug (including placebo) or trial medical device), and who are still within the follow-up period of a clinical study or within 5 half-lives of the trial drug at the time of screening (whichever is longer);
  6. Those with a suspected history of allergy to the study drug or any component of the study drug, those with allergic constitution, or those with a history of severe drug allergy;
  7. Those with a previous history of difficulty in blood collection or inability to tolerate venipuncture, such as those with needle phobia or blood phobia;
  8. Those with a previous history of gastric or intestinal surgery that, in the investigator's opinion, may affect drug absorption, or those with gastrointestinal diseases that may affect drug absorption;
  9. Those who have had a severe infection, severe trauma, or major surgery within 3 months before screening; or those who plan to undergo surgery during the trial period or within two weeks after its completion;
  10. Those who have donated blood or experienced blood loss of ≥ 200 mL in total within 1 month before screening, or ≥ 400 mL in total within 3 months before screening, or those who have received a blood transfusion within 8 weeks;
  11. Those who have smoked an average of ≥ 5 cigarettes per day within 3 months before screening; those who have consumed an average of more than 15 g of alcohol per day within 1 month before screening (5 g of alcohol is equivalent to 150 mL of beer, 50 mL of wine, approximately 17 mL of low-alcohol liquor, or 10 mL of high-alcohol liquor), or those who refuse to abstain from smoking, alcohol, and caffeinated foods or beverages during the screening period and the trial period, as well as those with special dietary requirements who cannot adhere to a unified diet;
  12. Those who, from 48 hours before taking the study drug until the end of the study, refuse to discontinue any beverages containing methylxanthines, such as caffeine (coffee, tea, cola, chocolate, etc.) or alcoholic beverages or any fruit juices, refuse to refrain from vigorous exercise, or have other factors that may affect drug absorption, distribution, metabolism, or excretion;
  13. Those with a high-sensitivity C-reactive protein level > 1.5 times the , or (PT), international normalized ratio (INR), or activated partial thromboplastin time (APTT) > 1.25 times the upper limit of normal during the screening period;
  14. Those who test positive in the infectious disease screening during the screening period (including surface antigen (HBsAg), virus antibody, antibody, and syphilis antibody);
  15. Those who have received a vaccination within 1 month before screening or plan to receive a vaccination during the trial or within 1 month after dosing;
  16. Women who are pregnant or lactating at the screening and baseline visits;
  17. Those who test positive in the alcohol breath test at the baseline visit;
  18. Those with a history of drug abuse or substance abuse; or those who test positive in the urine drug test at the screening and baseline visits;
  19. Staff of the research center or other personnel directly involved in the execution of the protocol;
  20. Other conditions that, in the investigator's opinion, make the participant unsuitable for participation in this trial, such as physiological or psychological diseases or conditions that may increase the risk of the trial, affect the participant's compliance with the protocol, or affect the participant's ability to complete the trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Queue 1

    Drug: HRS-5346

  • Experimental
    Queue 2

    Drug: HRS-5346

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: From before administration to one month after administration

  2. AUC0-t

    Time frame: From before administration to one month after administration

  3. AUC0-inf

    Time frame: From before administration to one month after administration

Secondary outcomes

  1. Tmax

    Time frame: From before administration to one month after administration

  2. CL/F

    Time frame: From before administration to one month after administration

  3. Vz/F

    Time frame: From before administration to one month after administration

  4. t1/2

    Time frame: From before administration to one month after administration

  5. Adverse event

    Time frame: From before administration to one month after administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Sep 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2026
First posted
Aug 7, 2026
StartEst.
Aug 2026
Primary completionEst.
Sep 2026
CompletionEst.
Oct 2026
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07752069
Responsible party
Sponsor
First posted
Aug 7, 2026
Start date
Aug 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Aug 7, 2026

Study contacts

Weijie Kong
Contact
weijie.kong.wk1@hengrui.com
0518-82342973
Yanli Dong
Contact
yanli.dong@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5346

Start the discussion